Dyadic International, Inc. Banner Image

Dyadic International, Inc.

  • Ticker DYAI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Dyadic International, Inc. Logo Image
  • 1-10 Employees
  • Based in Jupiter, Florida
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potentialMore to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.
4.8 / 5.0 (146)

Dyadic International, Inc. reports have an aggregate usefulness score of 4.8 based on 146 reviews.

Dyadic International, Inc.

Most Recent Annual Report

Dyadic International, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Dyadic International, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!